# BPC-157 TB-500 Research: The Constituent Tissue-Repair Literature > BPC-157 TB-500 research, constituent by constituent: BPC-157's transected-tendon and VEGFR2 angiogenesis findings, TB-500's actin-sequestration structure, and the absence of any combination trial. The blend has no trial of its own. What follows is the single-compound, mostly-rodent record for each peptide — tagged to the constituent it belongs to, and bounded by what the studies actually measured. ## BPC-157 and TB-500: The Two Peptides Behind the Wolverine Blend BPC-157 TB-500 research is the research record of two separate peptides read together. BPC-157 and TB-500 are the two peptides behind the Wolverine blend, and the case for documenting them as a pair rests entirely on the fact that their mechanisms are characterized independently. BPC-157 is the 15-amino-acid `GEPPPGKPADDAGLV` pentadecapeptide; its half-life was reported under `30 minutes` in a rat/dog pharmacokinetic study [1]. TB-500 is the `Ac-LKKTETQ` heptapeptide whose precise chemical identity — the N-terminal acetylated 17-23 fragment of Thymosin Beta-4 — was defined for doping-control reference [7]. The blend leans on the BPC-157 literature for one leg and the Thymosin Beta-4 literature for the other, which introduces a caveat the next sections return to repeatedly. ## What BPC-157 and TB-500 Have Been Studied For BPC-157 and TB-500 benefits, as discussed in research-community material, trace back to a specific preclinical record. Read honestly, the documented findings are these. ### Tendon and Ligament Findings In animal models, BPC-157 accelerated healing of a fully transected rat Achilles tendon across biomechanical, functional and microscopic measures and reversed 4-hydroxynonenal-induced growth inhibition of tendocytes into stimulation in vitro [5]. These are preclinical, single-compound results — not human or combination evidence. This is the flagship tendon finding behind the blend's BPC-157 leg. Doses were expressed per body weight (`10 microg/kg` or `10 ng/kg`, intraperitoneal in vivo), and the outcome was improved load-to-failure and collagen organization versus untreated controls [5]. ## Muscle and Wound Findings ### Does BPC-157 and TB-500 help muscle tears and recovery? Preclinical studies report BPC-157 aiding tissue repair via cytoprotective and angiogenic signaling, and Thymosin Beta-4 (TB-500's parent) promoting cell migration and regeneration. A 6-month Thymosin Beta-4 study in mdx mice, however, increased regenerating fibers but produced no gain in strength [4]. Findings are animal-model and single-compound. ### Does the BPC-157 TB-500 blend help wound healing? In animal models, Thymosin Beta-4 promoted angiogenesis and wound healing — including restored angiogenesis in aged animals with otherwise poor healing — and BPC-157 shows multi-tissue cytoprotection [6][2]. These are preclinical, single-compound results; the blend itself has no controlled wound-healing trial [11]. ## How the Two Peptides Work ### How does TB-500 work (actin / Thymosin Beta-4)? TB-500 is the `Ac-LKKTETQ` fragment of Thymosin Beta-4. X-ray crystallography established that Thymosin Beta-4 forms a 1:1 complex with monomeric G-actin and sequesters it by capping both ends, regulating the cytoskeletal dynamics that drive cell migration, re-epithelialization and endothelial mobilization [3]. ### How does BPC-157 work compared to TB-500? BPC-157 supplies a local cytoprotective and pro-angiogenic signal — VEGFR2-Akt-eNOS up-regulation and Src-Caveolin-1-eNOS vasomotor modulation [2][8]. TB-500 supplies an intracellular actin-sequestration signal — 1:1 G-actin binding via the `LKKTETQ` motif — that regulates cell migration [3]. They act through complementary but largely non-overlapping pathways, which is the basis of the unproven synergy claim. ## Is the Synergy Claim Proven? ### Is there any study showing BPC-157 and TB-500 work better together (synergy)? No. No peer-reviewed study has defined a synergy ratio, dose or endpoint for the two given together. A 2025 systematic review of BPC-157 — 36 studies, only 1 human, "no clinical safety data" — makes no mention of TB-500 or combination use [11]. "Synergy" is an extrapolation from each peptide's separate, largely non-overlapping mechanism. ### Are there human clinical trials on the BPC-157 + TB-500 combination? None. There are no controlled clinical trials of the BPC-157 plus TB-500 combination for any indication [13]. Human data exist only for the individual constituents and are thin: BPC-157 has three small pilot studies; "TB-500" human data are for full-length Thymosin Beta-4, not the heptapeptide [4]. ## The BPC-157 + TB-500 Stack: Combined-Use Rationale and the Evidence Gap The BPC-157 TB-500 stack — the same pairing under its other common name — is rationalized exactly as the blend is: complementary mechanisms covering different stages of repair. The combined-use rationale is plausible on paper because the two signals are distinct, with BPC-157 acting on the vasculature and TB-500 acting on the cytoskeleton [2][3]. The evidence gap is the whole story. A 2026 narrative review of approved and unapproved peptide therapies for musculoskeletal conditions — listing both BPC-157 and TB-500/Thymosin Beta-4 — concluded that many unapproved peptides show favorable tissue-repair outcomes in animal models but that rigorous human safety data are scarce, with potential for serious harm, and that such compounds operate largely outside regulatory oversight [12]. A 2025 narrative review reached the same bound for BPC-157: human data are extremely limited, large-scale trials are lacking, and it should be considered investigational [13]. The stack inherits both limits — and doubles the uncertainty by combining two unapproved peptides. For the access picture, see the [BPC-157 and compounding pharmacy access](/legal-status#compounding) page. --- A documentation-style reference on the BPC-157 TB-500 blend — each constituent's findings logged to its own studies, the combination left as an empty entry because no controlled trial exists, and the FDA 503A Category 2 status read from the source; no clinic compiled it and nothing here is dispensed or sold.